Navigation Links
VIVUS to Present at Four Upcoming Investor Conferences
Date:9/10/2010

MOUNTAIN VIEW, Calif., Sept. 10 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that VIVUS management will present an overview of the company at four investment conferences during the month of September.  The conference presentation schedule is as follows:Bank of America Merrill Lynch Global Healthcare Conference Presented by: Timothy Morris, chief financial officerSeptember 16, 2010 at 2:30 p.m. BST Bank of America Merrill Lynch Financial Centre, London, UKStifel Nicolaus 2010 Healthcare ConferencePresented by: Dr. Wesley Day, vice president, clinical development September 17, 2010 at 9:45 a.m. EDTFour Seasons, Boston, MAUBS Global Life Sciences ConferencePresented by: Timothy Morris, chief financial officerSeptember 22, 2010 at 12:30 p.m. EDTThe Grand Hyatt, New York, NYThe Fifth Annual JMP Securities Healthcare ConferencePresented by: Timothy Morris, chief financial officerSeptember 28, 2010 at 8:30 a.m. EDTThe Palace Hotel, New York, NYA live audio webcast and 30-day archive of the presentations will be available at http://ir.vivus.com.

About VIVUS VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead product in clinical development, QNEXA®, has completed phase 3 clinical trials for the treatment of obesity and an NDA has been filed and accepted by the FDA, with an action date of October 28, 2010. QNEXA is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. MUSE® (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information a
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. VIVUS to Present at Two Upcoming Investor Conferences
2. VIVUS Reports Third Quarter 2009 Highlights and Financial Results
3. VIVUS Announces Positive Results From Two Phase 3 Studies; Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-Morbidities
4. VIVUS to Present at Four Upcoming Healthcare Conferences
5. VIVUS to Present at the Canaccord Adams 29th Annual Global Growth Conference
6. VIVUS to Present at the Needham and Company Life Sciences Conference
7. Data on VIVUS Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting
8. VIVUS Reports First Quarter 2009 Financial Results and Highlights
9. Paratek to Present Clinical Data at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy
10. Lexicon to Present at Stifel Nicolaus Healthcare Conference
11. WaferGen Corporate Presentation to be Webcast at Rodman and Renshaws 12th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... MISSISSAUGA, ON , July 11, 2014 /CNW/ - ... Canada approved APTIOM TM (eslicarbazepine acetate) for use ... partial-onset seizures in patients with epilepsy who are not ... not indicated for use in patients under 18 years ... the most common neurological disorders and according to Epilepsy ...
(Date:7/10/2014)... 2014 Women in the West ... an additional family planning option. Sayana® Press has ... all levels of the health system and in ... widely used contraceptive—Pfizer’s Depo-Provera® (depot medroxyprogesterone acetate)—with the ... the first of four African countries expected to ...
(Date:7/10/2014)... Understanding the need for better quality and higher ... that currently exists in this area, ChanTest has recently ... validated ion channel and GPCR cell lines. ChanTest’s ... channels control many critical physiological functions throughout the body. ... to treat a variety of human diseases. , ...
(Date:7/10/2014)... Robert Harman, DVM, Founder and CEO of Vet-Stem, Inc., ... the relaunch of his highly informative blog, now named Stem ... What are Stem Cells ?” Dr. Harman’s purpose for ... the basics of stem cell therapy so that pet owners ... treatment when considering regenerative medicine. , A veterinarian by trade, ...
Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3
... Data to be presented at American Society of Anesthesiologists Annual ... continuous hemoglobin (SpHb) and Oxygen Content (SpOC) monitor with ... ... Calif., Oct. 17 Masimo, the inventor,of Pulse CO-Oximetry(TM) and ...
... announced today a significant redesign of its web site, including ... database of published synthetic gene applications and a revamped Bioinformatics ... DNA and protein sequences. , ... ...
... Shandong, China, Oct. 17 /Xinhua-PRNewswire-FirstCall/ --,Shengtai Pharmaceutical, ... Company,), a leading manufacturer and distributor of ... announced that it has,completed factory improvements providing ... cornstarch facility., The Company,s improvement of ...
Cached Biology Technology:Five New Clinical Studies Show Value of Masimo PVI & PI 2Five New Clinical Studies Show Value of Masimo PVI & PI 3Five New Clinical Studies Show Value of Masimo PVI & PI 4Five New Clinical Studies Show Value of Masimo PVI & PI 5DNA2.0 Launches New Website: Enhanced Design and Free Bioinformatics Tools Demonstrate DNA2.0's Customer Focus 2Shengtai Pharmaceutical Completes Factory Improvements Resulting in Operational and Environmental Benefits 2Shengtai Pharmaceutical Completes Factory Improvements Resulting in Operational and Environmental Benefits 3
(Date:7/10/2014)...  Aware, Inc. (NASDAQ: AWRE ), a ... on June 26, 2014 that its Board of Directors ... share, or approximately $40 million in total.  The Board ... a payment date of July 24, 2014.  The Company ... an ex-dividend date for this special cash dividend.  An ...
(Date:7/10/2014)... , July 2, 2014  Unisys Corporation,s (NYSE: ... Unisys Nederland N.V., today announced that it has been selected ... and manage a new Basic Provision Biometrics solution for penitentiaries ... Unisys won the contract with a solution based on its ... The term of the contract is up to seven years, ...
(Date:7/10/2014)... July 2, 2014 NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication ... Mr. Gino Pereira was interviewed on July 1 ... Tampa Florida . Mr. Pereira discusses the company,s ... Harris and how the Wocket™ aims to replace a ... Cedric Harris tells Gino he has never ...
Breaking Biology News(10 mins):NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 2Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 4
... Building on these findings, the Helmholtz scientists and their ... pathogenesic mechanisms of the disease and gain perspectives for ... study have been published online in the journal ... international research consortium QTSCD (QT Interval and Sudden Cardiac ...
... cholesterol level, working out on his treadmill. The ... his heart,s electrical system had managed to stay on the ... sudden cardiac death, which annually claims more than a quarter ... detectable molecules circulating in the blood makes the prediction of ...
... Technology and Innovation in Global BiometricsGAITHERSBURG, Md., March ... ) has been named the Biometrics Systems Integrator ... recognizing the Corporation,s leadership in developing innovative biometrics ... and Sullivan based the award on a rigorous ...
Cached Biology News:Genetic risk factors identified for sudden cardiac death 2Genetic risk factors identified for sudden cardiac death 3Hopkins scientists ID 10 genes associated with a risk factor for sudden cardiac death 2Hopkins scientists ID 10 genes associated with a risk factor for sudden cardiac death 3Lockheed Martin Named Biometrics 'Company of the Year' by Frost and Sullivan 2
Porcine Aortic Smooth Muscle Cells (PAOSMC) (>500,000 cells)...
... BioControl is a major step forward ... liquid handling system - with one ... cone modules. All five single channel ... fit one handle. The lightweight handle ...
Bovine Pulmonary Artery Smooth Muscle Cells (BPASMC) (>500,000 cells)...
... known as smooth muscle cell specific protein, is ... various tissues such as intestine, lung and uterus. ... calponin. SM22 alpha expression has been reported in ... vascular and visceral forms. It is also reported ...
Biology Products: